In a long-term collaboration, Ksilink and myriamed jointly established and validated an induced pluripotent stem cell (iPSC)-derived model of dilated cardiomyopathy (DCM), which will now be exploited by the newly created joint venture ‘Myrtil Biotechnologies’. DCM is a life-threatening disease in which the heart becomes enlarged and cannot pump blood effectively anymore. About 1 in […]
continue reading